Immune cells get reprogrammed in first human trial
Exhausted immune cells that accumulate as we age. One company thinks it can reprogramme them to behave like young cells again. The first test in humans is about to begin.
British biotech company Sentcell is preparing for a Phase 1 clinical study targeting aged T cells (white blood cells that coordinate immune defence). The study focuses on exhausted or senescent CD4+ T cells, which accumulate with age and become less effective. The treatment is administered by intramuscular injection and is designed to reactivate key pathways involved in immune dysfunction.
Telomere structures in the bloodstream
The mechanism Sentcell is investigating is unusual. Laboratory research suggests that rejuvenated CD4+ T cells may release structures containing telomere material (the protective caps on chromosomes) into the bloodstream. Researchers call these structures ‘telomere rivers’ and are investigating whether they could influence the health of other tissues. This idea remains under active investigation and has not yet been demonstrated in humans.
Earlier mouse studies showed promising results, but the sample sizes were small and the reported lifespan extension was strikingly large. Those are red flags that call for caution in interpreting the findings. The upcoming Phase 1 study has the primary goal of assessing safety and biological activity, not demonstrating clinical benefit.
Who participates and what will be measured?
Participants will be carefully selected, with a focus on adults showing evidence of immune dysfunction, including immune aging and chronic viral infections. They will undergo detailed immune profiling before and after treatment. Investigators will examine whether the therapy can restore features of healthy immune function.
The launch of a Phase 1 trial is encouraging. It signals that independent scientists find the hypothesis sufficiently compelling to test in people. But the road from Phase 1 to a proven treatment is long, and most candidates do not make it to the finish line.
Search terms: CD4 T cell exhaustion immune aging, extracellular telomere structures, immune rejuvenation clinical trial